Evotec Receives $5M Milestone Payment From Bristol Myers Squibb Following FDA IND Acceptance Under Strategic Protein Degradation Partnership

Bristol-Myers Squibb Company +2.36%
Evotec SE -1.95%

Bristol-Myers Squibb Company

BMY

52.41

+2.36%

Evotec SE

EVO

3.01

-1.95%

  • Milestone payment reflects continued progress under strategic research collaboration addressing high-need patient populations
  • FDA clearance of IND application triggered a US$ 5 m milestone payment to Evotec
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via